Genprex price target lowered to $7.50 from $8 at Alliance Global Partners

Alliance Global Partners lowered the firm’s price target on Genprex to $7.50 from $8 and keeps a Buy rating on the shares post the Q2 report. The firm remains positive on the prospects for Genprex’s development pipeline in the second half of 2024, and notes a number of milestones have been hit to date this year.